BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
下载
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [1] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Chan-yuan Wu
    Qian Wang
    Jian Shi
    Xiu-ying Zhang
    Rong Du
    Jie-ruo Gu
    Qi-huan Liu
    Jiao Yu
    Jia-wei Xu
    Yan-jie Zhang
    Hao Zhu
    Meng-tao Li
    Xiao-feng Zeng
    Rheumatology and Therapy, 2023, 10 : 1609 - 1622
  • [2] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Wu, Chan-Yuan
    Wang, Qian
    Shi, Jian
    Zhang, Xiu-Ying
    Du, Rong
    Gu, Jie-Ruo
    Liu, Qi-Huan
    Yu, Jiao
    Xu, Jia-Wei
    Zhang, Yan-Jie
    Zhu, Hao
    Li, Meng-Tao
    Zeng, Xiao-Feng
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1609 - 1622
  • [3] SAFETY AND EFFECTIVENESS OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 24-WEEK DATA OF ALL-CASE POSTMARKETING SURVEILLANCE IN CLINICAL USE IN JAPAN
    Pile, Kevin
    Tamura, Naoto
    Atsumi, Tatsuya
    Okamoto, Nami
    Takahashi, Nobunori
    Nakajima, Atsuo
    Nakajima, Ayako
    Fujii, Takao
    Matsuno, Hiroaki
    Tsujimoto, Naoto
    Nishikawa, Atsushi
    Ishii, Taeko
    Takeuchi, Tsutomu
    Kuwana, Masataka
    Takagi, Michiaki
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 30 - 30
  • [4] MULTICENTER 24-WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF TACROLIMUS IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS
    Hur, J.
    Hong, S.
    Kim, S.
    Kim, G.
    Choi, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1404 - 1404
  • [5] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BUILD STUDY
    Emery, Paul
    Krogulec, Marek
    Blanco Alonso, Ricardo
    Rossini, Maurizio
    Raeman, Frank
    Walker, David
    Ghizdavescu, Andrei Petru
    Irto, Ildiko
    Luz Rentero, Maria
    Casillas, Marta
    de la Torre, Inmaculada
    Dougados, Maxime
    RHEUMATOLOGY, 2016, 55 : 60 - 60
  • [6] Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis
    Dabal, Tracey D.
    Haltom, Matthew B.
    Patel, Puja P.
    Son, Christine K.
    Joglekar, Kiran P.
    Groeschell, Charles M.
    Chumpia, Mason M.
    Kamal, Sehrish F.
    Seth, Ankur
    Jackson, Christopher D.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (05) : 288 - 292
  • [7] Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: 24-week phase 3 RA-BEACON study results
    Zamani, O.
    Combe, B.
    Tony, H. P.
    Sanchez Burson, J.
    Tahir, H.
    Ostergaard, M.
    Augendre-Ferrante, B.
    Beselin, A.
    Larsson, E.
    Casillas, M.
    Smolen, J.
    SWISS MEDICAL WEEKLY, 2016, 146 : 3S - 3S
  • [8] Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
    Fleischmann, Roy
    Alam, Jahangir
    Arora, Vipin
    Bradley, John D.
    Schlichting, Douglas E.
    Muram, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] OPEN LABELED, MULTICENTER 24-WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF TACROBELL® IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS
    Hong, S. -J.
    Choi, J. -Y.
    Kim, S. -S.
    Kim, Y. S.
    Kim, S. -H.
    Kim, G. -T.
    Choi, S. J.
    Lee, M. S.
    Hur, J. -W.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1043 - 1043
  • [10] Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study
    Zamani, O.
    Combe, B.
    Tony, H-P
    Burson, J. S.
    Tahir, H.
    Ostergaard, M.
    Augendre-Ferrante, B.
    Beselin, A.
    Larsson, E.
    Casillas, M.
    Smolen, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 21 - 22
12345